Heron Therapeutics, Inc. (0J4V.L)
0J4V.L Stock Price Chart
Explore Heron Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze 0J4V.L price movements and trends.
0J4V.L Company Profile
Discover essential business fundamentals and corporate details for Heron Therapeutics, Inc. (0J4V.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
29 Jan 2018
Employees
122.00
Website
https://www.herontx.comCEO
Craig Alexander Collard
Description
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
0J4V.L Financial Timeline
Browse a chronological timeline of Heron Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 10 Nov 2025
Upcoming earnings on 4 Aug 2025
Revenue estimate is $37.93M.
Earnings released on 6 May 2025
EPS came in at $0.01 surpassing the estimated -$0.01 by +260.51%, while revenue for the quarter reached $38.90M, beating expectations by +1.71%.
Earnings released on 27 Feb 2025
EPS came in at $0.02 surpassing the estimated -$0.03 by +178.30%, while revenue for the quarter reached $40.78M, beating expectations by +11.20%.
Earnings released on 12 Nov 2024
EPS came in at -$0.03 surpassing the estimated -$0.04 by +20.78%, while revenue for the quarter reached $32.81M, missing expectations by -12.19%.
Earnings released on 7 Aug 2024
EPS came in at -$0.06 falling short of the estimated -$0.04 by -54.27%, while revenue for the quarter reached $36.02M, missing expectations by -0.18%.
Earnings released on 7 May 2024
EPS came in at -$0.02 surpassing the estimated -$0.07 by +71.95%, while revenue for the quarter reached $34.67M, beating expectations by +5.13%.
Earnings released on 13 Mar 2024
EPS came in at -$0.07 surpassing the estimated -$0.15 by +53.61%, while revenue for the quarter reached $34.23M, beating expectations by +9.63%.
Earnings released on 15 Nov 2023
EPS came in at -$0.17 surpassing the estimated -$0.29 by +41.03%, while revenue for the quarter reached $31.43M, missing expectations by -3.72%.
Earnings released on 15 Aug 2023
EPS came in at -$0.35 falling short of the estimated -$0.22 by -57.31%, while revenue for the quarter reached $31.76M, beating expectations by +0.21%.
Earnings released on 12 May 2023
EPS came in at -$0.27 falling short of the estimated -$0.22 by -26.97%, while revenue for the quarter reached $29.62M, missing expectations by -0.24%.
Earnings released on 24 Mar 2023
EPS came in at -$0.17 surpassing the estimated -$0.32 by +47.34%, while revenue for the quarter reached $30.03M, beating expectations by +10.24%.
Earnings released on 30 Sept 2022
EPS came in at -$0.38 surpassing the estimated -$0.38 by +0.25%, while revenue for the quarter reached $26.56M, missing expectations by -1.49%.
Earnings released on 30 Jun 2022
EPS came in at -$0.55 falling short of the estimated -$0.54 by -2.68%, while revenue for the quarter reached $27.63M, beating expectations by +12.54%.
Earnings released on 31 Mar 2022
EPS came in at -$0.63 falling short of the estimated -$0.49 by -28.99%, while revenue for the quarter reached $23.46M, beating expectations by +3.76%.
Dividend declared on 15 Mar 2022
A dividend of $0.29 per share was announced, adjusted to $0.29.
Earnings released on 22 Feb 2022
EPS came in at -$0.54 surpassing the estimated -$0.58 by +7.08%, while revenue for the quarter reached $20.66M, missing expectations by -19.86%.
Earnings released on 3 Nov 2021
EPS came in at -$0.62, while revenue for the quarter reached $22.44M.
Earnings released on 30 Sept 2021
EPS came in at -$0.51, while revenue for the quarter reached $23.23M.
Earnings released on 31 Mar 2021
EPS came in at -$0.58, while revenue for the quarter reached $20.02M.
Earnings released on 31 Dec 2020
EPS came in at -$0.68, while revenue for the quarter reached $20.61M.
Earnings released on 30 Sept 2020
EPS came in at -$0.64, while revenue for the quarter reached $19.97M.
0J4V.L Stock Performance
Access detailed 0J4V.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.